RGI-2001
GvHD prevention (allogeneic HSCT)
Phase 2Active
Key Facts
About REGiMMUNE
Treg‑focused biotech delivering novel immunotherapies for GvHD, autoimmunity and oncology.
View full company profileGvHD prevention (allogeneic HSCT)
Treg‑focused biotech delivering novel immunotherapies for GvHD, autoimmunity and oncology.
View full company profile